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Abstract 
The anti-epileptic Gabapentin  has a dose-dependent bioavailability as it is absorbed from 
the limited distributed and saturable L-amino acid transporter. Drug derivatization  using 
prodrug approach has been demonstrated as a very important means to overcome such 
related pharmacokinetic and pharmaceutical drawbacks. However, in this approach, 
enzymes are mandatory for the interconversion of many prodrugs and many prodrug-
activating enzymes may be decreased or increased due to genetic polymorphism and age-
related physiological changes. Unraveling the mechanisms of a number of enzyme models 
(intramolecular processes) has contributed to the design of efficient prodrug linkers that 
can be covalently attached to commonly used drugs; these drugs have the ability to release 
the active drug chemically, but not enzymatically. Such enzyme models were utilized in 
my prodrug design approach which was accomplished using computational calculations 
based on molecular orbital and molecular mechanics methods.  
Using DFT molecular orbital at B3LYP 6-31G (d, p) level and molecular mechanics 
(MM2) calculations of the intramolecular proton transfer in a number of Kirby   enzy e 
models four Gabapentin prodrugs were designed to provide a medicine with higher 
bioavailability than its parent drug (Gabapentin), and to provide systems having the 
potential to release Gabapentin in a controlled matter.  
It was found that the intramolecular proton transfer rate of the designed Gabapentin 
ProD1-ProD4 is largely determined on the strain energies of the reactions‟ tetrahedral 
intermediates; no correlation was found between the cyclization rate and distance between 
the two reactive centers (rGM). Therefore, the intra-conversion rates of the Gabapentin 
prodrugs can be programmed according to the nature of the prodrug linker. 
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Chapter One 
Introduction 
 
1.1 Background 
Generally, a drug is characterized by its biological and physicochemical properties. Drugs, 
with unsuitable physicochemical properties, might provide inefficient and undesirable 
therapeutic profiles. Nowadays, finding a drug with good physicochemical properties and 
pharmacokinetic profile is considered as one of the most important issues in the drug 
discovery field.  
Presently several known oral medicines suffer from poor pharmacokinetic and 
bioavailability profiles. Therefore, for drugs clinical profiles to be improved, the 
physicochemical properties of those parent drugs should be modified. The pharmacokinetic 
or pharmacological barrier's such as low absorption, lack of site specificity, insufficient 
chemical stability, poor solubility, toxicity, and unacceptable taste/odor should be greatly 
eliminated [1].  
Among the various approaches to minimize the undesirable drug properties while retaining 
the desirable therapeutic activity is the prodrug approach [2, 3]. Prodrug design is an 
efficient approach which is based on transiently modified drug's pharmaceutical properties 
to overcome some of the related pharmacokinetic and pharmaceutical problems [4]. The 
prodrug approach has been successfully applied to a wide variety of drugs;  about 10% of 
worldwide marketed drugs can be classified as prodrugs [1, 5, 6].  
Generally, prodrugs can release their active drugs by two main prodrugs approaches: the 
traditional approach by which a prodrug interconversion occurs via enzymatic reaction and 
the novel approach which is based on enzyme models (intramolecular process) that have 
been advocated to assign the factors playing a dominant role in enzyme catalysis [7-9]. In 
this approach, there is no need for an enzyme to catalyze the prodrug interconversion. The 
interconversion rate is determined only by the factors govern rate-limiting step of the 
intramolecular process [7, 10, 11]. In this novel approach, the design of prodrug is 
accomplished using computational calculations (computational chemistry) based on 
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molecular orbital and molecular mechanics methods and correlations between 
experimental and calculated rate values for some intramolecular processes [7, 10]. 
Computational chemistry uses the principles of computer science to assist in solving 
chemical problems. It uses the theoretical chemistry results incorporated into efficient 
computer programs for calculating the structures, physical and chemical properties of 
molecules. Few decades ago, the world has viewed an increasing number of medicinal 
chemists, biochemists and further researchers in various fields who have started using 
computational methods to better understand the mechanism of intramolecular processes for 
a number of enzyme models as well as calculating molecular properties of ground and 
transition states and design of some novel prodrug linkers. The application of 
computational chemistry has many advantages mainly by helping to reduce the need for 
access to expensive laboratory time, test equipment and chemicals [10, 12, 13]. 
Today, modern computational methods such as those based on quantum mechanics (QM) 
and molecular mechanics (MM) methods could be exploited for the design of innovative 
prodrugs for common use drugs [10]. 
 
 Quantum Mechanics (QM): 
Quantum Mechanics (QM also known as Quantum Physics, or Quantum Theory) is the 
laws of physics for very small and light objects, such as electrons and nuclei. It can provide 
a mathematical description of the behavior of electrons and thus of chemistry. In QM, the 
Schrodinger equation is solved for the wave-functions of our particles, giving information 
about the probability of measuring various values for its physical properties [14, 15]. 
 
Schrodinger Equation 
The Hamiltonian operator, H, depends on the kinetic and potential energies of the nuclei 
and electrons in the atom or molecule. The wave-function, , will give us information 
about the probability of finding the electrons in different places in the molecule. The 
energy, E, is related to the energies of individual electrons which can be used to help 
interpret electronic spectroscopy. 
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The Quantum mechanics includes ab initio, semi-empirical and Density Functional Theory 
(DFT) methods [16-18]. 
 
Ab initioMethods  
Ab initio is an essential calculation method based on a computational solution of the 
electronic Schrodinger equation by a well-defined      xi   i n (  “  de   he i   y”) 
[4]. When all approximations are sufficiently small in magnitude, and when the finite set of 
basic functions tends toward the limit of a complete set, we can use the ab initio method. 
Ab initio electronic structure methods have the advantage of making converge to the exact 
solution. This method is used to determine the positions of a collection of atomic nuclei, 
the total number of electrons in the system, calculate the electronic energy, electron 
density, and more properties of systems containing tens, or even hundreds of atoms. 
However, the treatment of large condensed-phase systems (e.g., proteins in aqueous 
solution) entirely by ab initio methods is extremely expensive computationally; they take a 
significant amount of computer time, memory, and disk space. 
 
 Semi-Empirical Methods 
The semi-empirical quantum methods depend on the Hartree–Fock formalism, and they are 
very important in the study of systems (large molecules) that are out of reach of more 
accurate methods [19]. Semi-empirical calculations are much faster than their ab initio 
counterparts. The most used semi-empirical methods are MINDO, MNDO, MINDO/3, 
AM1, PM3, and SAM1[20]. 
Semi-empirical methods make many approximations; their results can be trust-worthy and 
accurate only when the molecule being computed is close enough to the molecules in the 
database used to parameterize the method. 
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Density Functional Theory 
The Density Functional Theory (DFT) is another widely used, popular and useful quantum 
mechanical modeling method available in physics and chemistry. In this theory, the energy 
of the molecule is a functional of the electron density, where the electron density is a 
function with three variables– x-, y-, and z-position of the electrons, and the determination 
of the electron density is independent of the number of electrons [16, 21].  
DFT can be used to determine the properties of many-electron systems with a significant 
increase in computational accuracy but without the additional increase in computing time. 
It is used to calculate electronic structures (principally the ground state) and energies for 
medium-sized systems (30–60 atoms) of biological and pharmaceutical interest but is not 
restricted to the second row of the periodic table [21]. 
Nevertheless, problems such as the incomplete treatment of dispersion can adversely affect 
the DFT degree of accuracy in the treatment of systems which are dominated by 
dispersion. Moreover, the need to determine the most appropriate method for a particular 
application force the practitioner to consult the literature, prior to choosing a DFT method, 
to determine the suitability of that choice for that particular problem or application. 
DFT methods such as B3LYP/6-31G(d) are oftentimes considered to be standard model 
chemistry for many applications. However, Some DFT methods are specifically designed 
for specific applications, such as the MPW1K hybrid method which is designed for the 
determination of kinetics problems. 
 
 Molecular mechanics 
Molecular mechanics is a mathematical approach used to calculate the energy, optimized 
geometry, dipole moment, and many other physical properties of a given molecule. 
Macromolecules such as proteins, large crystal structures, and relatively large solvated 
systems are widely calculated by this method. Molecular mechanics is fast, and large 
molecule like a steroid (e.g. cholesterol) can be optimized only in a few seconds on a 
powerful desktop computer. However, determination of parameters, such as a large number 
of unique torsion angles present in structurally diverse molecules, makes a limitation for 
this method [12]. 
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In order to investigate the functional mechanisms of biological macromolecules based on 
their 3D and electronic structures, ab initio methods are preferable to be utilized. However, 
the treatment of large systems (e.g., proteins in aqueous solution) entirely by ab initio 
methods is extremely expensive computationally.  The size of the system, which ab initio 
calculations can handle, is relatively small despite the large sizes of bio-macromolecules 
surrounding solvent water molecules. Accordingly, ab initio calculations can be used in 
isolated models of areas of proteins such as active sites. Whereas the remainder can be 
treated more approximately by means of Molecular Mechanics (MM).  The technologies 
for coupling quantum chemical methods to molecular mechanic methods [mixed quantum 
mechanics (QM)/MM)] have become an essential component of the theoretical arsenal, 
enabling realistic modeling of even the most complex molecular structures [22]. 
 
1.2 Gabapentin 
Gabapentin is 1-(aminomethyl)cyclohexaneacetic acid (Figure 1) with a molecular weight 
of 171.237 g/mol and a molecular formula of C9H17NO2. It has a dose-dependent 
bioavailability (27-60%).  
 
 
 
 
 
 
Gabapentin,  a structural analog of GABA (gamma-aminobutyric acid), is an anti-epileptic 
used for the treatment of epilepsy [23] and neuropathic pain [24, 25]. Although its exact 
mode of action is not entirely known, gabapentin appears to have a unique effect on 
voltage-dependent calcium ion channels at the postsynaptic dorsal horns. It may inhibit the 
alpha-2-delta (α2δ)     ni   f  he N-type voltage-dependent calcium ion channels on 
ne   n .  f e   he  inding     he α2δ     ni , it reduces calcium influx that is needed for 
the release of neurotransmitters-especially excitatory amino acid- from presynaptic 
 
Figure 1: Chemical structure of Gabapentin 
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neurons. This channel becomes up-regulated when nerves are stimulated, such as in 
epileptic conditions or associated with neuropathology [26].  
Despite that the gabapentin has a similarity in structure to GABA; there is no direct 
interaction between gabapentin with GABA receptors. [27] Gabapentin is not bind to 
GABAA or GABAB receptors and is not an inhibitor of GABA uptake or degradation 
[28]. 
Gabapentin is an amino acid that exists at physiological pH as a zwitterion as it is doubly 
charged; its native permeability to membrane barriers within the body is low as its water 
soluble and GI tract absorption are binding to the L gamma amino acid transport system in 
the proximal small bowel. However, gabapentin molecules can cross membrane barriers 
more easily because it is a substrate of the system L transporter of the gut and a small 
amount of gabapentin transported via passive diffusion [29-31]. 
 
1.3 Research Problem 
The bioavailability of gabapentin is dose-dependent as the drug is absorbed from the 
proximal small bowel into the blood stream by the L-amino acid transport system and 
because this transport system is capacity limited [29]. 
Dose-dependent pharmacokinetics, high variability between patients, and potentially 
ineffective drug exposure occurs due to the fact that the absorption of gabapentin occur in 
a limited region of the small intestine and at clinically used doses it saturates [22, 32]. 
Surprisingly, the bioavailability of gabapentin decreases with increasing dosages; the oral 
bioavailability of gabapentin is approximately 60%, 34%, 33%, and 27% following 900, 
1200, 3600, and 4800 mg/day given in 3 divided doses, respectively.  Most importantly, 
the range of doses where bioavailability decreases concur with doses reported being useful 
for the treatment of neuropathic pain [33]. 
However, the effectiveness of Gabapentin is limited as a result of inherent pharmacokinetic 
deficiencies. The variability of Plasma exposure to gabapentin after oral dosing due to 
saturation of its absorption pathway, a low-capacity transporter found only in the upper 
small intestine make it unpredictable and lack of absorption in the large intestine is another 
problem with gabapentin saturates [32]. 
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Saturation of the gabapentin transport pathway may be responsible for the observed dose-
dependent, and this causes a decrease in bioavailability. Gabapentin absorption is mediated 
by a low-capacity solute transporter, probably an L-type amino acid transporter which is 
located mainly in the upper small intestine [33]. 
As a result, the prediction of the Gabapentin dose necessary to achieve an optimal 
therapeutic effect in a given patient is often difficult, and the desired treatment response 
may not be achieved. One of the causes that necessitate the frequent dosing is the short 
half-life of gabapentin (about 5–7 h) which is a cause of noncompliance in epileptic 
patients and missed doses which can reduce clinical effectiveness [32, 33]. 
 
1.4 Thesis Objectives 
1.4.1 General Objective 
The main goal of this research was to design prodrugs, with a better bioavailability and 
having the potential to release their parent drug in a controlled manner using a variety of 
different molecular orbital and molecular mechanics methods and correlations between 
experimental and calculated reactions rates. 
1.4.2 Specific Objective 
►Calculations of Kirby's enzyme model mechanism for the design of Gabapentin 
prodrugs which should have the following properties: 
1- Converted to Gabapentin in a controlled manner. 
2- The linker attached to the drug moiety and the whole Gabapentin prodrug moiety 
should have no toxicity and safe. 
3- To provide systems with enhanced bioavailability compared to the parent 
Gabapentin. 
 
1.5 Research Questions 
1. Would the DFT calculation method for Gabapentin prodrugs be capable of 
producing reaction rates similar to that obtained by Kirby? 
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2. Would the DFT calculations be good methods for the design of Gabapentin 
prodrugs that can be cleaved in physiological environments to furnish the active 
drugs and a non-toxic moiety and have better bioavailability than their parent drug? 
  
 10 
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Chapter Two 
Literature Review 
2.1 Prodrugs 
A drug is a chemical entity which is used in the treatment, prevention and/or diagnosis of 
disease. Generally, a drug is characterized by its biological and physicochemical properties 
such as solubility and polarity, thus a drug with good properties results in efficient 
bioavailability and consequently effective treatment of disease. However, several studies 
have shown that many known oral medicines suffer from disagreeable pharmacokinetic 
and bioavailability profiles which are attributed to the undesirable physiochemical 
properties. Therefore, these issues should be significantly considered early in the drug 
discovery process to improve the drug's therapeutic efficacy and cost-effectiveness.  
An important approach that has been developed to modify and improve various undesirable 
physicochemical properties is a prodrug design. The prodrug approach, that was first 
introduced by Albert, can be used to synthesize new chemical entities that have superior 
efficacy, selectivity, and reduced toxicity. Hence an optimized therapeutic outcome can be 
accomplished.  
Actually, around 10% of all marketed drugs are prodrugs, 20% of small molecular weight 
drugs approved between 2000 and 2008 were prodrugs, and about 12% was the share of 
prodrugs in the drug market between 2008 and 2017 [34]. 
The use of the term ''prodrug'' usually involves a covalent link between a drug and a 
chemical moiety (linker) that can be enzymatically or chemically degraded in vivo to 
release the parent active drug which can exert the desired therapeutic effect. Ideally, the 
prodrug should be converted to the parent drug and non-toxic moiety as soon as its goal is 
achieved followed by the subsequent rapid elimination of the released linker group [2, 35]. 
In some prodrug strategies, the target is to improve the pharmacokinetic profile like 
absorption of the original drug by altering in their physiochemical parameters, like 
lipophilicity (HLP Balance) through the linking of specific functional groups or 
macromolecules to the naked drugs [36-41]. Other prodrug strategies aim to make 
targeting drugs [42] or make drugs more resistant to hydrolysis and metabolism by the 
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addition of a bulky alkyl group like t-butyl in close proximity to the functional group [43, 
44], or by removing or replacing a metabolically vulnerable group [45].  
The major challenge facing the prodrug approach strategy is that enzymes are mandatory 
for the interconversion of many prodrugs to their active parent drugs. And many prodrug-
activating enzymes may be decreased or increased due to genetic polymorphism, age-
related physiological changes, or drug interactions, leading to adverse pharmacokinetic, 
pharmacodynamics, and clinical effects. In addition, there are wide interspecies variations 
in both the expression and function of the major enzyme systems activating prodrugs. 
However, to overcome all problems associated with prodrug interconversion by enzymes, a 
novel chemical approach for drugs that contain hydroxyl, phenol, or amine groups can be 
used to design prodrugs based on intramolecular processes (enzyme models) that were 
advocated to assign the factors playing a dominant role in enzyme catalysis [7-9]. In this 
approach, there is no need for an enzyme to catalyze the prodrug interconversion; the 
interconversion rate is determined only by the factors governing the rate-limiting step of 
the intramolecular process [7, 10, 11]. In the novel prodrug approach, the design of 
prodrug is accomplished using computational calculations (computational chemistry) based 
on molecular orbital, molecular mechanics methods, and correlations between 
experimental and calculated rate values for some intramolecular processes [7, 10]. 
 
2.2 Enzyme Models Used in the Prodrug Design 
The rate of the reactions carried out in the presence of enzyme exceeded non-enzymatic 
bimolecular counter parts. For example, the rate constant of reactions catalyzed by 
cyclophilin are enhanced by 10
5
, and those by orotidine monophosphate decarboxylase are 
enhanced by 10
17 
[46]. 
This amazing efficiency of the enzyme to catalyze biochemical reactions has motivated 
many organic chemists and biochemists to study the mechanisms of how enzymes catalyze 
biochemical reactions via examining particular intramolecular (enzyme model) process 
[47-52]. 
During the past sixty years, scientists have provided many studies that interpret how 
enzymes catalyze biochemical transformations.Today, the consensusis that the catalytic 
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activity of an enzyme is based on the combined effects of catalysis by functional groups 
and the ability to reroute intermolecular reactions through alternative pathways by which 
substrates bind to preorganized active sites. 
The significant rate of acceleration achieved by enzymes is related to the binding of the 
substrate within the confines of the enzyme pocket called the active site. The binding 
energy of the resulting enzyme-substrate complex is the main driving force and the most 
important contributor to catalysis. This binding energy is used to overcome prominent 
physical and thermodynamic factors that create barriers f    he  e   i n (Δ ) in all bio-
conversions catalyzed by enzymes. 
In the past five decades, proposals have been made from attempts to interpret changes in 
reactivity versus structural variations in intramolecular systems. Among these proposals 
and hypothesis are the following: 
(I) „„O  i      ee ing‟‟ proposed by Koshland, it is suggests a rapid intramolecularity arises 
from a severe angular dependence of organic reactions, such as in the lactonization of 
rigid hydroxy acids [53]. 
(II) „„   xi i y   ien   i n‟‟ in intramolecular processes (near attack conformation) as 
proposed by Bruice and demonstrated in the lactonization of di-carboxylic acids semi-
esters [54-56]. 
(III) „„S e e        i n   n    ‟‟    ed  n  he   n e    f f eezing      e   e in     
productive rotamer as advocated by Cohen [57-59]. 
(IV)   nge ‟  „„    i  e       hy   he i ‟‟ whi h         e   h    he    e  f  e   i n 
between two reactive centers is proportional to the time that the two centers reside 
within a critical distance [60-64]. 
(V)   i  y‟       n    n fe    de    n  he   id-catalyzed hydrolysis of acetals and N-
alkylmaleamic acids which demonstrated the importance of hydrogen bonding 
formation in the products and transition states leading to them [8, 65-72]. 
Understanding these intramolecular processes can draw a basis for utilizing these enzyme 
models as linkers to certain drugs for synthesizing of prodrugs that they will undergo non-
enzymatic (chemical) conversion to their parental drugs in predicted rates and with higher 
bioavailability than their corresponding parental drugs. 
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Many prodrugs were designed   ing  i  y‟  enzy e   del, such as the anti-malarial 
Atovaquone [73], antihypertensive atenolol [74], tranexamic acid for treatment of heavy 
bleeding conditions [75], antibacterial cefuroxime [76] and the antiviral acyclovir prodrugs 
[77]. In addition to the use  f  enge ‟   e     id enzy e   de  to design of dopamine 
prodrugs for the treatment  f    kin  n‟  di e  e [78]. As well, prodrugs for masking the 
unpleasant taste of atenolol (anti-hypertensive) [74] and the bitterless paracetamol were 
designed, synthesized and their kinetics were studied [74].  
The         i n     dy  n  i  y‟    e     enzyme  model also directed to the design of 
novel prodrug such as, aza-nucleoside (to treat myelodysplastic syndromes) [92], the 
decongestant phenylephrine [13], atovaquone [73, 79, 80] and statins for treatment of high 
cholesterol levels in the blood [81]. In these prodrugs, the hydroxyl group of the active 
drug was linked to the acetal moiety upon the exposure of such prodrug to the 
physiological environment; it has the potential to convert to its parent active form with 
   e   h     e    e y de e  ined  n  he            fe    e   f  he  inke  ( i  y‟    e   ). 
Recently, Karam n‟  g     h   ex    ed  he  e h ni  i     hw y   f   n   e   f in   -
molecular processes using ab initio and density functional theory (DFT) molecular orbital 
methods [82]. The results obtained were found to be in accordance with that report by 
Kirby and Lancaster and Kluger and Chin. 
Among the studied intramolecular processes are the following: 
 Acid-catalyzed lactonization of hydroxy-acids as researched by Cohen [83] and 
Menger [84]. 
 SN2-based ring closing reactions as studied by Brown, Bruice, and Mandolin [85]. 
      n    n fe   e ween  w   xygen  in  i  y‟    e     [76, 86], proton transfer 
 e ween ni   gen  nd  xygen in  i  y‟  enzy e   de   [76, 86] and proton transfer 
f     xygen         n in    e  f  i  y‟  en   e he   [87]. 
Results of these studies indicate the necessity to further explore the reaction mechanisms in 
order to determine the factors affecting the reaction rate such as: (1) The driving force for 
enhancements in the rate of intramolecular processes is both entropy and enthalpy effects. 
In the cases by which enthalpic effects were predominant such as ring-cyclization and 
proton transfer reactions proximity or/and steric effects were the driving force for rate 
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accelerations. (2) The distance between the two reactive centers determine the nature of the 
reaction being intermolecular or intramolecular (when  he di   n e  e ween  he  w  
 e   ing  en e   i        2.4    he  e   i n i  in      e       whe e   when  he di   n e i  
3   nd    e   he  e   i n   efe    he in e    e          e  ). (3) In SN2-based ring-
closing reactions leading to three-, four- and five-membered rings the gem-dialkyl effect is 
more dominant in processes involving the formation of an unstrained five-membered ring, 
and the need for directional flexibility decreases as the size of the ring being formed 
increases. (4) Accelerations in the rate for intramolecular reactions are a result of both 
entropy and enthalpy effects. Finally (5) in  i  y„    e     y  e     n effi ien       n 
transfer between two oxygens atoms and between nitrogen and oxygen were affordable 
when strong hydrogen bonds are developed in the products and the corresponding 
transition states leading to them [82, 84, 85]. 
 
2.3 Computationally Designed Gabapentin Prodrugs  Based on 
Intramolecular Amide Hydrolysis            Enzyme Models 
Proton transfer reaction is one of the most common processes catalyzed by enzymes. Due 
to the fact that reactions of an enzyme active site and substrate are related to functional 
groups held in close proximity, many scientists have encouraged exploiting 
intramolecularity in modeling enzyme catalysis. Both enzymes and intramolecularity are 
similar in that the reacting centers are held together, noncovalently with the enzymes, and 
covalently with the intramolecular process. The tremendous high efficiency of enzymes 
catalysis depends on a combination of some factors that most of them have been 
recognized, but none of them was fully understood. Although the devoted research to the 
chemistry of enzyme catalysis is growing rapidly, a number of several factors remain to be 
studied [88, 89]. 
The mechanism of acid-catalyzed hydrolysis of N-alkylmaleamic acid to maleamic acid 
derivatives and amines (Figure 2) was studied by Kirby. The results have revealed that the 
amide bond cleavage is due to intramolecular nucleophilic catalysis by the adjacent 
carboxylic acid group and the rate of hydrolysis was largely dependent on the substitution 
on the carbon-carbon double bond [90]. The rate-limiting step for the hydrolysis is the 
dissociation of the tetrahedral intermediate.  
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Figure 2: Chemical structures of Nalkylmalic acids 1-7 
 
Based on AM1 semiempirical calculations, in 1990, Katagi had demonstrated that the rate-
limiting step is the formation of the tetrahedral intermediate, not its dissociation [91]. Later 
on, Kluger and Chin investigated that the intramolecular hydrolysis rate-limiting step is a 
function of both the basicity of the leaving group and the solution acidity [92]. 
In order to determine the factors playing a dominant role in proton transfer processes, 
Karaman and coworkers have computationally studied Kirby's intramolecular acid-
catalyzed hydrolysis of N-alkymaleamic acids 1-7 using DFT calculation method. The 
result confirmed that the reaction proceeds in three steps: the first step is proton transfer 
from the carboxylic acid to the adjacent amide carbonyl carbon and the second step of the 
reaction involves  nucleophilic attack of the carboxylate anion onto the protonated 
carbonyl carbon and finally dissociation of the tetrahedral intermediate to provide the 
product.  Moreover, the result demonstrates that the rate-limiting step is dependent on the 
reaction medium. When the calculations were run in the gas phase, the rate-limiting step 
was the tetrahedral intermediate formation, whereas when the calculations were conducted 
in the presence of a cluster of water the rate-limiting step is the dissociation of the 
tetrahedral intermediate.  
Furthermore, the results showed that the efficiency of the intramolecular acid-catalyzed 
hydrolysis is largely dependent on the substitution of the carbon-carbon double bond, when 
the leaving group (methylamine) in 1-7 was replaced with a group having a low pKa 
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value.The formation of the tetrahedral intermediate is the rate-limiting step, and the rate of 
hydrolysis was found to be linearly correlated with the strain energy of the tetrahedral 
intermediate or the product. Systems having strained tetrahedral intermediates or products 
experience low rates and vice versa [65, 77, 93]. 
Gabapentin is an amino acid and it is highly charged at physiological pH; both the amino 
group and the carboxyl group are ionizable, existing as a zwitterion with a pKa 1 of 3.7 and 
a pKa 2 of 10.7 [31].  
Since Gabapentin is doubly-charged and its pka is outside the range (6-9), Gabapentin 
tends to be ionized and poorly absorbed through membrane tissue. However, converting 
the structure of Gabapentin (neutralizing the ionized amine group ) into amide prodrugs 
(Figure 3) will provide a change in the pka and subsequently an improvement in the 
absorption [31]. 
Based on DFT calculations for the acid-catalyzed hydrolysis of several N-alkylmaleamic 
acid derivatives (Figure 2) four Gabapentin prodrugs were designed (Figure 3) using four 
linkers (Figure 4). 
 
Figure 3: Proposed Gabapentin Prodrugs Design 
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Figure 4: Linkers used in the Gabapentin Prodrugs 
 
As shown in Figure 5, Gabapentin ProD1-ProD4 have a carboxylic group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the prodrug) where the combination of both 
moieties assure a relatively moderate HLB, and which will equilibrate between the ionic 
and the free acid forms especially in a physiological environment of  pH 5.5-6.8 (intestine). 
Thus, it is expected that Gabapentin ProD1-ProD4 may have better bioavailability than 
the parent drug due to neutralizing the ionized amine group which results in absorption 
improvement. In addition, these prodrugs may be used in different dosage forms (i.e. 
enteric coated tablets, topical use and etc.) because of their potential solubility in organic 
and aqueous media due to the ability of the carboxylic group to be converted to the 
corresponding carboxylate anion in a physiological pH of around 6.0. 
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Figure 5: Acid - catalyzed hydrolysis of Gabapentin prodrugs ( ProD1-ProD4) 
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Chapter three 
Computational (Design) Section 
 
Calculation Programs and Methods Used in the Thesis 
3.1 Calculation Programs 
The following programs were exploited in the design calculations: 
 
3.1.1 Arguslab 
Arguslab is free molecular modeling, graphics, and drug design program that offers quite 
good on-screen molecule-building facilities with a moderate library of useful 
molecules.This program can create 3D geometry optimized models using the UFF force 
field, as it covers all elements of the Periodic Table because it is not restricted to known 
atom types in its parameterization, though it does use some common ones. The resulting 
energies are distinctly different from those obtained using some of the more conventional 
force fields, and wherever possible one needs to re-optimize at a higher level. For this, 
Arguslab offers geometry optimization using the MNDO, AM1 or PM3 semi-empirical 
methods, as well as single point calculations. There are also single point semi-empirical 
calculations using Extended Huckel (for a bigger element coverage) or ZINDO (for excited 
states for UV/visible absorption prediction). Version 3.1 of Arguslab has good facilities for 
calculating electron density or orbital surfaces at the semi-empirical levels and displaying 
them [94]. 
Argus lab writes its own format of molecule file, like .xml, but it can also write xyz files 
for input to other programs, e.g. Molden. It creates (and leaves behind) a lot of temporary 
files which need to be managed.  
To start work using Arguslab, we press the 'New' button (top left) to get a new molecule 
screen, or press the 'Open' button to read in a molecule which has saved previously in your 
Argus directory.  
In Arguslab, we need to save our molecule with whatever name we want before doing a 
geometry optimization as well as after ward so that all the ancillary files will have the right 
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names. If we forget to change the file name before modifying a molecule, files will be 
saved automatically with the same name used previously. As a problem to this program, it 
should be noted that not all the required data can be fully saved. 
It is best not to maximize the molecule window because then its title bar will display the 
name by which we are currently saving the files. Just drag its bottom right corner so that it 
fills most of the Arguslab worktop. To stop using Argus lab, click File Exit, if we have 
molecule windows open, this will just close one of these. We need to do it repeatedly to 
close all the windows (if we have several open) and then stop the program. 
3.1.2 Gaussian 2009 
Gaussian 09 is the latest version in the Gaussian series of electronic structure programs, 
used by chemists, chemical engineers, biochemists, physicists, and other scientists. It 
utilizes fundamental laws of quantum mechanics to predict energies, molecular structures, 
vibration frequencies, and numerous molecular properties for systems in the gas phase and 
in solution, and it can model their ground state and excited states. The use of Gaussian 
makes the theoretical study of basic research in established and emerging areas of chemical 
interest possible, and also to study molecules and reactions of definite or potential interest 
including both stable species and compounds which are difficult or impossible to observe 
experimentally either due to their nature (e.g., toxicity, combustibility, radioactivity) or 
their inherent fleeting nature (e.g., short-lived intermediates and transition structures). 
Gaussian 09 takes as an input of the (.gjf) file produced by GaussView and runs the 
analyzer to produce a solution to the problem. A typical command line for the solver is 
given below. G09.exe input_file.gjf output_file.out  
Checkpoint file: output_file.chk 
 An output text file (.out) is created so that it can be read and inspected by a human. In 
addition, a checkpoint file (.chk) is also produced that it may be processed by a computer 
to produce further detailed information. 
Dissecting the output file, the Z-matrix represents how the software knows the molecular 
geometry (structure). Notice that the molecule has no charge and a multiplicity of 1 (all 
pairedelectrons). The structure is also represented as a more standard xyz coordinate 
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system. The distance matrix shows the distance of each atom from the other atoms in units 
of angstroms. 
3.1.3 Molden 
Molden is a computational program package made for displaying molecular densities from 
the ab initio packages, Games-US, Games-UK, Gaussian, MOLPRO and from semi-
empirical packages such as MOPAC, and supports a number of other formats. Molden can 
interpret and convert information from all these programs into its own format, thereby 
providing a standardizing tool. It can display molecular orbitals or electron density as 
contour plots or 3D grid plots and output to a number of graphical formats, e.g.postscript, 
X-Windows, VRML, povray, OpenGL, tekronix4014 and hpgl, hp2392. It can animate 
reaction paths and molecular vibrations.  The Molden program can also be used as a visual 
Z-matrix molecule editor, thereby allowing users to create the molecule of their choice and 
being able to save the geometry in the Molden format [63]. Molden format incorporates 
numerous data stores in a text file; each piece of data is headed by a key term e.g. [MO] for 
molecular orbitals, [STO] for slater type orbital basis sets, plus many others like [GTO], 
[GEOMETRIES], etc.  
Molden format also features a stand-alone force field program (Ambfor) which can 
optimize geometries with the combined Amber (protein) and GAFF (small molecules) 
force fields. Atoms type can be done automatically and interactively from within Molden 
as well as firing optimization jobs. 
3.2 Calculation Methods 
 
The Becke three-parameter, hybrid functional combined with the Lee, Yang, and Parr 
correlation functional, denoted B3LYP, were employed in the calculations using density 
functional theory (DFT).  All calculations were carried out using the quantum chemical 
package, Gaussian-2009, and based on the restricted Hartree-Fock method [95]. The 
starting geometries of all calculated molecules were obtained using the Argus Lab program 
[96] and were initially optimized at the HF/6-31G level of theory followed by optimization 
at the B3LYP/6-31G(d,p). Total geometry optimizations included all internal rotations. 
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Second derivatives were estimated for all 3N-6 geometrical parameters during 
optimization. The search for the global minimum structure, in each of the systems studied, 
was accomplished by 36 rotations of the carboxyl group about the bond C3-C4 in 
increments of 10° (i.e. the variation of the dihedral angle C2C3C4C5, see Chart 1) and 
calculation of the energies of the resulting conformers. 
 
.  
Chart  1: Schematic representation of the reactants in the cyclization reactions of 
Gabapentin prodrugs. (rGM) is the distance between the nucleophile (O1) and the 
electrophile (C6). 
 
An energy minimum (a stable compound or a reactive intermediate) has no negative 
vibrational force constant. The Reaction Coordinate Method [97] was used to calculate the 
activation energy in Gabapentin ProD1-ProD4. The transition state structures for all 
systems studied were obtained from the increase in the distance between the phenolic 
oxygen (O) and the carbonyl carbon (C) in increments of 0.1 Å (see Chart1). The 
activation energy values for the cyclization reactions of all di-carboxylic semi-esters were 
calculated from the difference in energies of the global minimum structures (GM) and the 
derived transition states (TS). The transition state structures were verified by their only one 
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negative frequency. Full optimization of the transition states was accomplished after 
removing any of the constraints imposed while executing the energy profile. The activation 
energies, obtained from the DFT at B3LYP/6-311 + G (d,p) level of theory for all 
molecules,were calculated with and without the inclusion of solvent (dielectric constant of 
78.39, water). The calculations, with solvent, were performed using the integral equation 
formalism model of the Polarizable Continuum Model (PCM) [98-102]. In this model, the 
cavity is created via a series of overlapping spheres. The employed Radii type was the 
United Atom Topological Model on Radii optimized for the PBE0/6-31G (d) level of 
theory. 
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Chapter Four 
Result and Discussion 
 
The kinetic study for the acid-catalyzed hydrolysis of N-alkylmaleamic acids 1-7 by 
 i  y‟  g     (Figure 2) revealed that the amide bond cleavage occurs due to 
intramolecular nucleophilic attack which is catalyzed by the adjacent carboxylic acid 
group; the rate-limiting step is the tetrahedral intermediate dissociation [103]. 
      n‟  DFT calculations on the acid-catalyzed hydrolysis of Kirby`s N-alkylmaleamic 
acids revealed that the rate-limiting step is the collapse of the tetrahedral intermediate in an 
aqueous medium, whereas the rate-limiting step is the formation of the tetrahedral 
intermediate in the gas phase. Furthermore, the calculations showed the following: 
A correlation between the acid-catalyzed hydrolysis efficiency  
1. The difference between the strain energies of intermediate and product, and intermediate 
and reactant.  
2. The distance between the hydroxyl oxygen of the carboxylic group and the amide 
carbonyl carbon.  
3. The angle of attack.  
The calculations, moreover, revealed that the acid catalyzed reaction occurred following 
three steps: (1) proton transfer from the carboxylic group to the adjacent amide carbonyl 
oxygen, (2) nucleophilic attack of the carboxylate anion onto the protonated carbonyl 
carbon; and (3) dissociation of the tetrahedral intermediate to provide products (Figure 6). 
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Figure 6: Proposed mechanism for the hydrolysis of Gabapentin ProD1 
According to the calculation results of Kirby`s N-alkylmaleamic acids model, i proposed 
some prodrugs of Gabapentin by linking this drug with anhydride linker such as maleic, 
succinic, glutaric, and hexahydro-4-methylphthalic (Figure 4) aiming to: (1) improve the 
bioavailability of the parent drugs, (2) to make prodrug that is capable of releasing the 
parent drug in a sustained release manner. 
As shown in Figure 4, Gabapentin ProD1-ProD4 have a carboxylic group (hydrophilic 
moiety) and a lipophilic moiety (the rest of the prodrug) where the combination of both 
moieties secures a modified HLB. 
In this chapter, i reported the DFT at B3LYP 6-31G (d,p) level calculations of ground state 
and transition state structures, vibrational frequencies, and reaction trajectories for 
intramolecular proton transfer in Gabapentin prodrugs ProD1-ProD4. 
 
Computations were directed toward elucidation of the transition and ground state structures 
(global minimum, intermediates, and products) for the acid-catalyzed hydrolysis of 
Gabapentin ProD1–ProD4 in the gas phase and in the water phase (a dielectric constant of 
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79.38). It is expected that the stability of the chemical entities (GM, TS, and P.) will be 
different in the gas phase compared to that in water (a relatively high dielectric constant). 
 
4.1 General Consideration 
Continuing the strategy for exploring enzyme models in the design of novel prodrugs, 
 i  y   enzy e   de   (Acid-catalyzed hydrolysis) was employed in the design of 
Gabapentin prodrugs (Figure 5) with the potential to be more bioavailable than their active 
parent drug. Furthermore, it is planned that the intraconversion rate of Gabapentin 
prodrugs to Gabapentin can be programmed according to the nature of the prodrug linker. 
 
Because the free energy of the reactant is strongly dependent on its conformation. The 
orientation of the carboxylate anion to the amide carbonyl moiety is very important and 
affecting the mode and rate of the cyclization reaction. Therefore, the identification of the 
most stable conformer (Global Minimum, GM) f   e  h  f  i  y‟  N-alkylmaleamic acids 
1–7 and Gabapentin prodrugs ProD1–ProD4 are crucially important. The global minimum 
search was achieved by 360 rotation of the carboxylic group about the C3-C4 bond (i.e. the 
variation of the dihedral angle C2C3C4C5 see Chart 1) and calculation of the 
conformational energies. 
 
In the DFT calculations of the starting geometries in Gabapentin ProD1-ProD4, two 
different types of conformations were considered: one in which the carboxylic hydroxyl 
proton is syn to the amide group and another in which it is anti (Chart 1). The global 
minimum search for Gabapentin ProD1- ProD4 revealed that all of them exist in the syn 
orientation (Figure 7). 
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4.2 Optimized Geometries for the Entities Involved in the Acid-Catalyzed 
Hydrolysis in Gabapentin ProD1- ProD4 
4.2.1 Global Minimum Geometries (GM) 
The calculated B3LYP/6-31 G (d,p) geometries along with selected bond distances for the 
global minimum structures of Gabapentin ProD1GM-ProD4GM are illustrated in 
Figure7. 
 
 
Figure 7: DFT optimized structures for the global minimum (GM) structures in Gabapentin 
ProD1-ProD4. 
 
Inspection of the optimized structures for Gabapentin ProD1GM-ProD4GM indicates that 
the calculated DFT values for the intermolecular distance ( rGM) values were in the range of 
2.93Å – 5.39Å (Figure 7) where the global minimum for ProD2 having the shortest 
distance (2.93Å) and for ProD3 the longest distance (5.39Å).  
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4.4.2 Transition State Geometries (TS): 
The calculated properties for the transition state geometries of Gabapentin ProD1-ProD4 
(ProD1TS-ProD4TS) are summarized in Table 1 and illustrated in Figure 8. 
 
Figure 8: DFT optimized structures for the transition state (TS) structures in the 
intramolecular proton transfer reaction of Gabapentin ProD1-ProD 4. 
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Table 1: DFT (B3LYP) calculated properties of transition states and ground states for the 
proton transfer reactions in Gabapentin ProD1-ProD4 in gas phase. 
B3LYP refer to values calculated by B3LYP/6-31G (d, p). (GM) and (TS) are global minimum and 
transition state structures, respectively. 
 
I has         ed  he en h   y    iv  i n ene gie  (Δ ‡ ), entropy activation energies 
(TΔS‡)   nd  he f ee    iv  i n ene gie  in  he g    h  e  nd w  e   h  e (Δ ‡ ) for the 
proton transfer reaction in these processes. The calculated energies are listed in Table 2. 
 
 
 
 
 
 
 
 
 
System 
B3LYP, Enthalpy, H 
(gas phase) in Hartree 
B3LYP, Entropy, S 
(gas phase) in Cal/Mol-
Kelvin 
B3LYP 
Frequency in Cm
-1
 
Gabapentin ProD1GM -939.0046604 140.187 ------- 
Gabapentin ProD1TS -938.9213672 149.181 411.75i 
Gabapentin ProD2GM -937.7590039 144.990 ------- 
Gabapentin ProD2TS -937.6888698 135.455 402.36i 
Gabapentin ProD3GM -978.3125683 161.378 ------- 
Gabapentin ProD3TS -978.245955 142.798 455.27i 
Gabapentin ProD4GM -1134.3792463 165.286 ------- 
Gabapentin ProD4TS -1134.3114699 158.008 465.39i 
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Table 2: DFT (B3LYP) calculated properties of transition states and ground states for the 
proton transfer reactions in Gabapentin ProD1-ProD4 in water phase. 
 
Table 3: DFT (B3LYP/6-31G (d,p) calculated kinetic and thermodynamic properties for 
the proton transfer in Gabapentin ProD1-ProD4. 
System 
 
∆ ‡ 
(GP) 
TΔS‡ 
(GP) 
∆ ‡ 
(GP) 
∆ ‡ 
(H2O) 
∆ ‡ 
(H2O) 
Gabapentin ProD1 52.27 2.85 49.42 20.47 17.61 
Gabapentin ProD2 44.01 -2.84 46.85 25.52 28.36 
Gabapentin ProD3 41.80 -5.54 47.34 23.24 28.78 
Gabapentin ProD4 42.53 -2.17 44.70 15.41 17.58 
∆ ‡ is the activ  i n en h   y ene gy (k   /   ). TΔS‡ is the activation entropy energy in kcal/mol. 
∆ ‡ is the activation free energy (kcal/mol). 
 
System B3LYP, Enthalpy, H 
(water phase) in 
Hartree 
B3LYP, Entropy, S 
(water phase) in 
Cal/Mol-Kelvin 
B3LYP 
Frequency in Cm
-1
 
Gabapentin ProD1GM -939.0529642 140.187 ------- 
Gabapentin ProD1TS -939.0203507 149.181 411.75i 
Gabapentin ProD2GM -937.8157879 144.990 ------- 
Gabapentin ProD2TS -937.7751217 135.455 402.36i 
Gabapentin ProD3GM -978.3768682 161.378 ------- 
Gabapentin ProD3TS -978.3398305 142.798 455.27i 
Gabapentin ProD4GM -1134.4264284 165.286 ------- 
Gabapentin ProD4TS -1134.4018707 158.008 465.39i 
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4.3 The role of the strain energy of the intermediates (EsINT) on the rate of 
the proton transfer in processes Gabapentin ProD1-ProD4. 
 We         ed    ing    inge ‟    2  e h d [104], the strain energy values for the 
intermediates (EsINT) in process Gabapentin ProD1-ProD4 to examine the role of the 
(EsINT) on the rate of the proton transfer in process Gabapentin ProD 1-ProD4. The MM2 
strain energies of the intermediates are listed in (Table 3). The calculated MM2 (EsINT) 
values for the process Gabapentin ProD1-ProD4 were examined for correlation with the 
calculated DFT    iv  i n f ee ene gie  (∆ ‡ ), a good correlation was found between the 
strain energy (EsINT) of the intermediates and the calculated activation energies in water ( 
R
2
 = 0.775  ) (Figure 9), whereas a random correlation was observed when the EsINT was 
plotted against the activation energies in the gas phase (R
2 
= 0.1644 ) (Figure 10). 
 
Figure 9: Plot of the DFT calculated ∆G‡ vs. steric energy for intermediate in water 
phase for Gabapentin ProD1-ProD4 
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Figure 10:       f  he  FT         ed ∆ ‡ vs. steric energy for intermediate in gase phase 
for Gabapentin ProD1-ProD4 
 
Examination of Figure 10 and Table 3 reveals that the rate of a proton transfer in processes 
Gabapentin ProD1-ProD4 is dependent on the strain energy of the tetrahedral 
intermediate. Systems having strained tetrahedral intermediates were found to be with low 
rates and vice versa. In order to further support this conclusion, the B3LYP 6-31G (d,p) 
activation energy values for 1-7 N-alkylmaleamic acid calculated in water ( see Table 3) 
were examined for correlations with log krel (relative rate) and the results are shown in 
(Figure 11). A linear correlation was found between the activation free energy of 1-7 N- 
alkyl maleamic acid in water phase and log krel with a correlation coefficient of R
2
= 
0.9316. 
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Table 4: DFT (B3LYP) calculated kinetic and thermodynamic properties for the acid-
catalyzed hydrolysis of 1-7 N-alkylmaleamic acid and Gabapentin ProD1- ProD4. 
System EsINT ∆ 
‡ 
Log krel[105] 
Gabapentin ProD1 14.216 
17.61342 
- 
Gabapentin ProD2 30.763 
28.3598 
- 
Gabapentin ProD3 26.5489 
28.778 
- 
Gabapentin ProD4 21.0860 17.579 - 
1 20.55 33.06 0 
2 16.16 20.05 4.371 
3 17.32 28.42 1.494 
4 27.89 38.11 -4.377 
5 19.25 23.12 2.732 
6 17.59 27.28 1.516 
7 18.55 27.55 1.648 
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Figure 11: Plot of the DFT         ed ∆ ‡ vs. relative rate (log Krel) in 1-7 N-
alkylmaleamic acid 
 
Furthermore, a linear correlation was found between the strain energies for intermediates 
of 1-7 N-alkylmaleamic acid (EsINT) and log krel (Figure 12) with a correlation coefficient 
of R
2
= 0.8835. 
 
 
Figure 12: Plot of the steric energy for intermediates of 1-7-N-alkylmaleamic acid vs. 
relative rate (log Krel) 
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Chapter 5 
Conclusions and Future Directions 
5.1 Conclusions 
Based on the DFT calculations, results of Kirby`s enzyme model (proton transfer in N-
alkylmaleamic acids), and novel Gabapentin prodrugs that can improve the bioavailability 
of the current medications to enhance effectiveness and to ease the use of the medications 
were designed.  
The designed Gabapentin prodrugs have a carboxylic group as a hydrophilic moiety and a 
lipophilic moiety (hydrocarbon skeleton ) where the combination of both groups ensures a 
modified hydrophilic-lipophilic balance value.  
The DFT calculation results revealed that the rate of a proton transfer in processes of 
Gabapentin ProD1-ProD4 and 1-7 is governed by strain effect of the tetrahedral 
intermediate. Systems, having strained tetrahedral intermediates, were found to be with 
low rates and vice versa.  
Therefore, it isexpected that the best candidates to fulfill the requirements needed to reach 
better bioavailability than the parent Gabapentin are Gabapentin ProD1 and ProD4. 
5.2 Future Directions 
Based on the DFT calculations made for systems 1-7 and the designed Gabapentin 
prodrugs, it is recommended to synthesize Gabapentin ProD1 and ProD4   ing  i  y‟  
synthetic procedure. In vitro, kinetic studies at different pH values should be made in order 
to be utilized for the in vivo pharmacokinetic studies which should be followed to 
determine the t1/2 values for the conversion of the Gabapentin ProD1 and ProD4 to its 
parent drug, Gabapentin 
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Supplementary Material  
Xyz Cartesian coordinates for the DFT optimized GM, TS and P in processes 
Gabapentin ProD1-ProD4. 
Gabapentin ProD1GM 
     C        0.000000    0.000000    0.000000 
     C        0.000000    0.000000    1.536890 
     C        1.416582    0.000000    2.170914 
     C        2.250449   -1.144128    1.536401 
     C        2.277365   -1.110648    0.000065 
     C        0.854989   -1.137305   -0.576591 
     C        1.226212   -0.274789    3.690979 
     N        2.419556   -0.060555    4.498153 
     C        2.576747    0.681668    5.637757 
     O        3.670152    0.761277    6.190541 
     C        2.152706    1.354836    1.933447 
     C        1.751971    2.455856    2.895688 
     O        0.601983    2.716920    3.209444 
     C        1.345791    1.385299    6.214963 
     C        1.726674    2.233201    7.425233 
     C        2.537710    3.458095    7.069192 
     O        2.572503    4.020596    5.988491 
     O        3.204568    3.942264    8.132311 
     O        2.816565    3.092396    3.398354 
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     H       -0.556132    0.862744    1.916717 
     H       -0.527728   -0.900475    1.884116 
     H        1.812309   -2.101500    1.852763 
     H        3.276662   -1.126305    1.927368 
     H        2.800987   -0.210648   -0.348724 
     H        2.856394   -1.963535   -0.373052 
     H        0.387982   -2.101928   -0.330919 
     H        0.885068   -1.075683   -1.670740 
     H       -1.032307   -0.079994   -0.360140 
     H        0.373964    0.961549   -0.376919 
     H        0.440504    0.379915    4.065521 
     H        0.870041   -1.308458    3.807373 
     H        3.274719   -0.526018    4.221162 
     H        0.614423    0.626392    6.518294 
     H        0.858597    2.004998    5.456799 
     H        0.821271    2.596228    7.928553 
     H        2.294954    1.652223    8.153511 
     H        3.675480    4.735842    7.825164 
     H        3.233968    1.221071    2.008316 
     H        1.947504    1.710842    0.918550 
     H        2.534813    3.643424    4.161950 
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Gabapentin ProD2 GM 
      C        0.000000    0.000000    0.000000 
      C       0.000000    0.000000    1.536391 
      C        1.422070    0.000000    2.158861 
      C        2.227043   -1.176019    1.541908 
      C        2.231918   -1.196916    0.004188 
      C        0.807533   -1.175577   -0.567014 
      C        1.264223   -0.228826    3.686336 
      N        2.507935   -0.415633    4.429705 
      C        3.122511    0.581108    5.117465 
      O        2.726820    1.741348    5.162532 
      C        2.186226    1.322397    1.906925 
      C        1.559284    2.594850    2.443197 
      O        2.431995    3.625371    2.350333 
      C        4.289630    0.178314    5.983440 
      C        5.542076   -0.176019    5.660065 
      C        6.152824   -0.325031    4.321412 
      O        7.311161   -0.645436    4.151895 
      O        5.318881   -0.063366    3.279756 
      O        0.433097    2.744615    2.869225 
      H       -0.566116    0.850977    1.920887 
      H       -0.515286   -0.909564    1.878733 
      H        1.776661   -2.115591    1.896255 
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      H        3.256135   -1.160338    1.919387 
      H        2.792395   -0.335516   -0.382866 
      H        2.769250   -2.086945   -0.344962 
      H        0.302249   -2.116600   -0.306214 
      H        0.836967   -1.131123   -1.662168 
      H       -1.034267   -0.041757   -0.361233 
      H        0.411591    0.946007   -0.377148 
      H        0.746367    0.621936    4.132401 
      H        0.650441   -1.122995    3.845186 
      H        2.969221   -1.311873    4.392171 
      H        4.063780    0.294947    7.042073 
      H        6.260791   -0.357940    6.452791 
      H        5.860878   -0.161974    2.478929 
      H        2.335938    1.488177    0.833719 
      H        3.191678    1.257663    2.334276 
      H        1.975431    4.395248    2.729464 
 
Gabapentin ProD3GM 
      C          0.000000    0.000000    0.000000 
      C          0.000000    0.000000    1.543674 
      C          1.452168    0.000000    2.090868 
      C          2.242215   -1.180313    1.484279 
      C          2.228702   -1.189167   -0.048485 
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      C          0.794756   -1.171027   -0.588327 
      C          -0.855737    1.160631    2.075247 
      C          -2.330374    1.017283    1.754271 
      O          -2.980117    2.200256    1.873133 
      C          1.552879   -0.067036    3.638928 
      N          1.500639    1.205721    4.349736 
      C          2.533520    2.055547    4.651266 
      O          2.322523    3.096332    5.266853 
      C          3.936027    1.635349    4.210339 
      C          5.005469    2.684855    4.526674 
      C          4.863967    3.962116    3.697422 
      C          5.989066    4.940912    3.938334 
      O          6.926601    4.784299    4.690061 
      O          5.839289    6.065371    3.192080 
      O          -2.902114   -0.011469    1.464370 
      H          -0.479546   -0.932444    1.875343 
      H          1.937894    0.934161    1.770349 
      H          1.813318   -2.122630    1.856575 
      H          3.276710   -1.148209    1.849277 
      H          2.767572   -0.305579   -0.418840 
      H          2.772149   -2.064635   -0.422783 
      H          0.294313   -2.114175   -0.328870 
      H          0.797720   -1.111226   -1.682870 
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      H          -1.032544   -0.032684   -0.360296 
      H          0.433340    0.947894   -0.353371 
      H          2.488268   -0.567961    3.906874 
      H          0.751480   -0.702379    4.034040 
      H          0.614357    1.535025    4.707122 
      H          4.185681    0.695203    4.720241 
      H          3.929343    1.398561    3.138173 
      H          5.994584    2.248812    4.354307 
      H          4.955789    2.943086    5.587608 
      H          4.841450    3.744815    2.620823 
      H          3.918932    4.463783    3.928826 
      H          6.596019    6.633833    3.413825 
      H          -0.503517    2.128977    1.703309 
      H          -0.808147    1.230085    3.167793 
      H          -3.917699    2.013110    1.694871 
 
Gabapentin ProD4GM 
      C          -2.389495   -1.676481   -0.837948 
      C          -2.577277   -0.455799    0.101371 
      C          -3.927409   -0.612699    0.850269 
      C          -5.128705   -0.862338   -0.074034 
      C          -4.894623   -2.070920   -0.991823 
      C          3.580517   -1.934546   -1.774376 
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      C          -1.460369   -0.436958    1.168856 
      N          -0.112097   -0.352874    0.622711 
      C          0.958570   -0.830626    1.327698 
      O          0.822066   -1.517070    2.336073 
      C          -2.538687    0.847713   -0.771788 
      C          -2.508358    2.164677   -0.030327 
      O          -1.551399    2.916818    0.057418 
      C          2.380679   -0.495416    0.831035 
      C          2.544450    0.412299   -0.421286 
      C          4.043471    0.640712   -0.721348 
      C          4.827257   -0.668873   -0.900395 
      C          4.640207   -1.568215    0.331642 
      C          3.161483   -1.813937    0.645222 
      C          1.867076    1.757074   -0.202308 
      O          0.792581    1.916955   -1.023569 
      C          6.306616   -0.393083   -1.190879 
      O          2.199949    2.579269    0.619598 
      O          -3.689669    2.481139    0.538644 
      H          -4.113855    0.259397    1.483776 
      H          -3.826093   -1.473456    1.525176 
      H          -2.245447   -2.560059   -0.201441 
      H          -1.464520   -1.565201   -1.414263 
      H          -3.671888   -1.122242   -2.508221 
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      H          -3.390109   -2.843542   -2.356829 
      H          -4.852186   -2.982334   -0.378955 
      H          -5.738122   -2.197684   -1.680499 
      H          -6.025224   -1.019186    0.536908 
      H          -5.332559    0.030600   -0.679805 
      H          -1.638067    0.394677    1.868919 
      H          -1.502604   -1.352463    1.763112 
      H          0.048345    0.316842   -0.116031 
      H          -3.414242    0.866383   -1.426267 
      H          -1.654809    0.834925   -1.413837 
      H          -3.560622    3.335991    0.985907 
      H          6.859300   -1.325687   -1.347161 
      H          6.777892    0.137031   -0.354786 
      H          6.430318    0.224020   -2.087514 
      H          0.220820    2.638990   -0.681992 
      H          4.140224    1.259439   -1.622096 
      H          4.473479    1.221478    0.104560 
      H          4.402413   -1.198297   -1.767840 
      H          5.122416   -1.091957    1.197764 
      H          5.152928   -2.525815    0.177721 
      H          2.701849   -2.388630   -0.171717 
      H          3.043095   -2.407598    1.554860 
      H          2.831091    0.045721    1.674263 
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 H        2.076419   -0.073620   -1.285475 
 
Gabapentin ProD1TS 
      C          0.000000    0.000000    0.000000 
      N          0.000000    0.000000    1.842000 
      C          1.328161    0.000000    2.356866 
      O          2.109162   -1.149474    1.866678 
      O          2.037957    1.158608    2.006044 
      C          2.954546   -1.617103    2.839154 
      O          3.736286   -2.507807    2.636537 
      C          2.715951   -0.836489    4.126332 
      C          1.373774   -0.142815    3.888606 
      C          -1.306123    0.597411   -0.509003 
      C          -2.464884   -0.336816   -0.044078 
      C          -1.514066    2.024074    0.049497 
      C          -0.417570    3.019458   -0.378276 
      C          -1.206278    0.632082   -2.080505 
      C          -1.047561    2.051523   -2.653209 
      O          -0.011867    2.866784   -1.869688 
      C          -4.288193   -0.017715   -1.620660 
      O          -3.837610    0.106837   -0.500608 
      H          -4.547259    0.687341    0.498080 
      H          -5.399312    0.946744    0.106534 
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      H          -2.488182    2.389793   -0.294852 
      H          -0.789334    4.033298   -0.192773 
      H          -2.093342    0.162813   -2.512643 
      H          -2.015072    2.568148   -2.629383 
      H          0.125256    3.851109   -2.330326 
      H          -0.764972    1.984178   -3.709932 
      H          0.961301    2.362872   -1.949046 
      H          -0.348629    0.024013   -2.400373 
      H          0.456689    2.899393    0.270435 
      H          0.868017    0.603917   -0.248896 
      H          0.156639   -1.042250   -0.278132 
      H          -0.408179   -0.909553    2.057038 
      H          1.278423    0.837969    4.355266 
      H          0.541305   -0.768935    4.223281 
      H          2.746951   -1.509160    4.985236 
      H          3.531471   -0.113870    4.235484 
      H          2.449521    0.994558    1.146729 
      H          -2.302856   -1.338648   -0.456568 
      H          -2.461111   -0.395484    1.046377 
      H          -1.562623    1.973304    1.140144 
 
Gabapentin ProD2TS 
      C          0.000000    0.000000    0.000000 
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      C          0.000000    0.000000    1.490709 
      O          1.340865    0.000000    1.886237 
      C          2.148453    0.147777    0.756693 
      C          1.261281    0.096374   -0.425250 
      N          -0.645044    1.664323    1.945585 
      C          0.155604    2.064972    3.270663 
      C          -0.015390    3.608093    3.397662 
      C          0.779484    3.903306    4.706215 
      C          0.391614    5.246095    5.338325 
      C          -1.084968    5.246968    5.798924 
      C          -1.960654    4.330785    4.912885 
      C          -1.420803    4.279150    3.478724 
      C          0.697745    4.201395    2.146535 
      C          1.832583    3.417218    1.517240 
      O          1.961065    3.239202    0.324402 
      O          -0.736752   -0.994764    2.064196 
      O          3.337692    0.300510    0.854309 
      O          2.728700    2.934503    2.415118 
      H          0.579679    3.105402    5.435243 
      H          1.851867    3.859050    4.498707 
      H          -2.112748    3.753101    2.810053 
      H          -1.360036    5.305106    3.091922 
      H          -1.978845    3.315756    5.329999 
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      H          -3.000552    4.676035    4.917960 
      H          -1.474658    6.271562    5.775208 
      H          -1.152349    4.918084    6.842740 
      H          1.053382    5.473219    6.181397 
      H          0.553602    6.049424    4.607636 
      H          0.840583    1.640095    3.415188 
      H          -0.784437    1.703203    4.101108 
      H          -1.640312    1.443507    1.991214 
      H          1.088384    5.193889    2.409968 
      H          -0.021488    4.340737    1.338727 
      H          3.350925    2.371771    1.916543 
      H          -0.563090   -0.988690    3.017432 
      H          1.640154    0.180298   -1.433406 
      H          -0.911504   -0.032832   -0.581338 
 
Gabapentin ProD3TS 
      C          0.000000    0.000000    0.000000 
      O          0.000000    0.000000    1.378591 
      C          1.190782    0.000000    2.147027 
      C          2.371215   -0.720958    1.546871 
      C          2.615915   -0.228636    0.117753 
      C          1.357738   -0.464554   -0.717210 
      N          0.742110   -0.961656    3.652642 
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      C          -0.145955   -0.154604    4.488579 
      C          -0.278140   -0.727346    5.927644 
      C          -1.341819    0.104853    6.684836 
      C          -1.422125   -0.203118    8.189379 
      C          -0.053438   -0.074315    8.870996 
      C          1.006931   -0.927969    8.163196 
      C          1.080324   -0.603715    6.664590 
      C          -0.666278   -2.242042    5.860950 
      C          -1.890658   -2.529140    5.027671 
      O          -3.027002   -2.594815    5.766375 
      O          1.522593    1.283287    2.488708 
      O          -1.022292    0.267717   -0.572058 
      O          -1.904645   -2.679575    3.821545 
      H          -2.326845   -0.029198    6.223213 
      H          -1.083979    1.166493    6.559026 
      H          1.421450    0.435604    6.556280 
      H          1.826664   -1.222915    6.157216 
      H          0.782725   -1.992326    8.316187 
      H          1.991523   -0.763491    8.617924 
      H          0.261146    0.979006    8.846145 
      H          -0.126672   -0.352022    9.929310 
      H          -2.145590    0.474100    8.659006 
      H          -1.816755   -1.216155    8.340380 
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      H          -1.152491   -0.026632    4.058857 
      H          0.293905    0.845781    4.593961 
      H          0.158648   -1.680203    3.215873 
      H          2.162905   -1.795512    1.556053 
      H          3.231892   -0.545206    2.194890 
      H          2.867686    0.837016    0.138494 
      H          3.463343   -0.753664   -0.333883 
      H          1.230253   -1.538909   -0.908105 
      H          1.391562    0.026930   -1.691880 
      H          -0.820991   -2.639880    6.865190 
      H          0.164043   -2.779266    5.397247 
      H          -3.748640   -2.757608    5.134320 
      H          0.699879    1.764218    2.664267 
 
Gabapentin ProD4TS 
     C       -3.182805   -1.651532   -0.691873 
     C       -2.729744   -0.435819    0.158307 
     C       -3.775262   -0.189680    1.277876 
     C       -5.220916   -0.088969    0.765713 
     C       -5.618818   -1.310320   -0.074245 
     C       -4.622600   -1.544863   -1.218715 
     C       -1.375513   -0.764949    0.838326 
     N       -0.279160   -0.952367   -0.127030 
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     C        1.017449   -0.459205    0.246649 
     C        2.055787   -0.611203   -0.891103 
     C        2.858205    0.704279   -0.799182 
     C        1.837384    1.670970   -0.223404 
     O        0.867105    0.967832    0.428632 
     C        2.904871   -1.894408   -0.920568 
     C        4.135376   -1.875855   -0.001455 
     C        4.971249   -0.595250   -0.171781 
     C        4.094693    0.631327    0.129113 
     O        1.818801    2.876822   -0.264609 
     O        1.546005   -0.993845    1.440659 
     C        6.220150   -0.613400    0.715852 
     C       -2.564205    0.798475   -0.773570 
     C       -1.881849    2.003911   -0.151006 
     O       -1.097350    2.637913   -1.048136 
     O       -2.006679    2.384721    0.995822 
     H       -3.504375    0.713582    1.830776 
     H       -3.717953   -1.030621    1.985173 
     H       -3.114204   -2.549726   -0.059813 
     H       -2.484918   -1.799179   -1.525364 
     H       -4.697815   -0.724590   -1.944950 
     H       -4.879448   -2.459134   -1.767229 
     H       -5.639053   -2.200478    0.571006 
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     H       -6.634157   -1.189857   -0.470424 
     H       -5.899759    0.021942    1.619488 
     H       -5.343546    0.822425    0.165118 
     H        4.666521    1.559745    0.023205 
     H        3.765812    0.574202    1.173922 
     H        5.297969   -0.533909   -1.222475 
     H        3.816968   -1.955676    1.043373 
     H        4.754086   -2.755555   -0.218075 
     H        3.244584   -2.031608   -1.955413 
     H        2.276929   -2.763809   -0.691208 
     H        1.457478   -0.569714   -1.807114 
     H        3.169410    1.057404   -1.786576 
     H       -1.120332    0.073635    1.491805 
     H       -1.512651   -1.650451    1.477247 
     H       -0.194261   -1.921991   -0.413806 
     H        6.853804   -1.477396    0.488708 
     H        5.945227   -0.671864    1.775565 
     H        6.822263    0.290866    0.576944 
     H       -3.545305    1.136592   -1.125823 
     H       -1.990759    0.515262   -1.657771 
     H       -0.560910    3.290157   -0.560492 
     H        0.958734   -0.732274    2.164880 
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    Gabapentin ProD1INT 
     O        0.000000    0.000000    0.000000 
     C        0.000000    0.000000    1.466375 
     C        1.495561    0.000000    1.922101 
     C        2.305355    0.051420    0.633372 
     C        1.289966    0.035577   -0.478149 
     N       -0.777972   -1.115920    1.985769 
     C       -2.212875   -0.992775    1.814098 
     C       -3.024237   -2.295807    2.025117 
     C       -4.514790   -1.910138    2.024654 
     C       -5.144115   -1.946443    3.405026 
     C       -4.236428   -1.365800    4.468895 
     C       -2.911928   -2.105570    4.551018 
     C       -2.654355   -2.980557    3.339628 
     C       -2.726464   -3.238537    0.850293 
     C       -3.458989   -4.541292    0.951724 
     O       -4.625000   -4.811433    0.656199 
     O       -0.527874    1.268564    1.759382 
     O        1.411760    0.043685   -1.694601 
     O       -2.698455   -5.574724    1.410152 
     H       -4.636300   -0.883297    1.591450 
     H       -5.084580   -2.611004    1.357966 
     H       -1.577757   -3.288827    3.323677 
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     H       -3.259377   -3.923318    3.421587 
     H       -2.078100   -1.364318    4.657897 
     H       -2.895336   -2.753897    5.464954 
     H       -4.753949   -1.407535    5.461393 
     H       -4.050767   -0.283540    4.242727 
     H       -6.107015   -1.373465    3.379509 
     H       -5.396944   -3.005326    3.672586 
     H       -1.629500   -3.461684    0.799183 
     H       -3.038955   -2.747880   -0.109037 
     H       -3.228350   -6.386525    1.435535 
     H       -2.469095   -0.592823    0.789245 
     H       -2.561586   -0.242003    2.580148 
     H       -0.423798   -1.974804    1.615016 
     H       -1.351241    1.382406    1.265536 
     H        1.734786   -0.907686    2.523535 
     H        1.669281    0.902044    2.557624 
     H        2.991192   -0.825128    0.532602 
     H        2.918234    0.984269    0.564408 
 
    Gabapentin ProD2INT      
      C        0.000000    0.000000    0.000000 
      C        0.000000    0.000000    1.517662 
      O        1.331367    0.000000    2.066738 
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      C        2.293378    0.755957    1.435984 
      C        2.019200    1.386177    0.103790 
      C        0.958961    0.667283   -0.645436 
      N       -0.750334    1.148220    2.044495 
      C       -0.765519    1.260987    3.487852 
      C       -1.534692    2.503104    4.004807 
      C       -1.272219    2.580947    5.514580 
      C       -2.155819    3.580119    6.234829 
      C       -3.624617    3.342199    5.946849 
      C       -3.885136    3.346791    4.453768 
      C       -3.033110    2.311149    3.746263 
      C       -1.054495    3.771737    3.294818 
      C        0.413839    3.799823    3.003139 
      O        1.235744    3.686540    4.082720 
      O       -0.472215   -1.259059    1.962767 
      O        3.335481    0.814021    2.084478 
      O        0.970685    3.955705    1.912304 
      H       -0.195902    2.849843    5.680304 
      H       -1.442500    1.563991    5.955629 
      H       -3.327229    1.289520    4.102836 
      H       -3.239908    2.358353    2.646139 
      H       -3.662993    4.363354    4.037400 
      H       -4.966869    3.131338    4.258775 
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      H       -3.936765    2.356222    6.377953 
      H       -4.240129    4.136428    6.440709 
      H       -1.971276    3.497281    7.337237 
      H       -1.880326    4.623548    5.932499 
      H       -1.298073    4.669040    3.922871 
      H       -1.583913    3.877072    2.310287 
      H        2.162090    3.697358    3.793400 
      H        0.306160    1.340554    3.831721 
      H       -1.212880    0.345330    3.972695 
      H       -1.674811    1.142411    1.662888 
      H        2.977054    1.415809   -0.478866 
      H        1.696481    2.452760    0.293186 
      H        1.009492    0.718128   -1.742214 
      H       -0.802239   -0.574276   -0.475901 
      H       -0.056326   -1.463066    2.811130 
 
    Gabapentin ProD3INT 
     C        0.000000    0.000000    0.000000 
     O        0.000000    0.000000    1.366804 
     C        1.232638    0.000000    2.130596 
     C        2.475605   -0.472738    1.338458 
     C        2.494806    0.172604   -0.028718 
     C        1.249806   -0.207367   -0.797776 
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     N        1.027530   -0.790031    3.346201 
     C       -0.188505   -0.499908    4.081247 
     C       -0.284631   -1.230104    5.446152 
     C       -1.674768   -0.915965    6.014610 
     C       -1.847619   -1.336267    7.461004 
     C       -0.747246   -0.789391    8.348073 
     C        0.619984   -1.166431    7.813265 
     C        0.799925   -0.693430    6.384184 
     C       -0.104709   -2.741517    5.273566 
     C       -0.806878   -3.276705    4.063958 
     O       -2.118862   -3.583500    4.241936 
     O        1.408012    1.379189    2.375000 
     O       -1.131490    0.152199   -0.460435 
     O       -0.337431   -3.496536    2.942533 
     H       -2.446253   -1.434353    5.386131 
     H       -1.849731    0.188430    5.933945 
     H        0.764210    0.426979    6.361600 
     H        1.808703   -1.002828    6.008750 
     H        0.749349   -2.278404    7.862323 
     H        1.414756   -0.707798    8.455794 
     H       -0.830796    0.326520    8.403515 
     H       -0.869468   -1.188578    9.387235 
     H       -2.840623   -0.967715    7.827711 
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     H       -1.865640   -2.454469    7.533553 
     H       -1.106470   -0.769209    3.480709 
     H       -0.222837    0.607486    4.277552 
     H        1.083343   -1.765430    3.116708 
     H        2.455592   -1.587032    1.239592 
     H        3.385339   -0.178750    1.920068 
     H        2.548321    1.286800    0.087461 
     H        3.403643   -0.158038   -0.592623 
     H        1.284945   -1.291771   -1.087271 
     H        1.170466    0.393728   -1.740923 
     H      -0.494488   -3.270560    6.182393 
     H        0.985486   -2.985297    5.165093 
     H      -2.493793   -3.916829    3.411058 
     H        0.584863    1.741467    2.726782 
 
Gabapentin ProD4 INT 
     C       -2.371717    1.546406   -1.127091 
     C       -3.190124    1.068449    0.056524 
     C       -2.198029    0.193807    0.842063 
     C       -1.097491   -0.167349   -0.222099 
     O       -1.214002    0.804651   -1.289088 
     C       -4.429974    0.358573   -0.469120 
     C       -5.007752   -0.613651    0.547022 
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     C       -3.950075   -1.651631    0.893661 
     C       -2.766209   -1.000468    1.575997 
     C       -6.253182   -1.275114   -0.006337 
     N        0.254546   -0.158678    0.339649 
     C        1.313274    0.004180   -0.639099 
     C        2.730505   -0.325516   -0.108645 
     C        3.710035    0.031750   -1.234350 
     C        5.122430   -0.456334   -0.982462 
     C        5.157646   -1.944055   -0.695467 
     C        4.241684   -2.290705    0.460970 
     C        2.822119   -1.824143    0.202714 
     C        3.031030    0.469120    1.162493 
     C        2.742689    1.933266    1.053963 
     O        2.850606    2.711032    0.103030 
     O       -1.442998   -1.378802   -0.869695 
     O       -2.552752    2.424663   -1.955924 
     O        2.333708    2.486424    2.231986 
     H        3.715994    1.145801   -1.368898 
     H        3.335519   -0.424652   -2.187925 
     H        2.404370   -2.391605   -0.669413 
     H        2.195420   -2.068425    1.098909 
     H        4.628663   -1.817859    1.400542 
     H        4.239703   -3.399721    0.620537 
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     H        4.837941   -2.509070   -1.608758 
     H        6.204791   -2.258194   -0.453457 
     H        5.748723   -0.233758   -1.884808 
     H        5.573409    0.102301   -0.122162 
     H       -5.196942    1.126878   -0.745036 
     H       -4.168485   -0.209052   -1.401342 
     H       -5.282792   -0.047867    1.479301 
     H       -3.607167   -2.166180   -0.041977 
     H       -4.387768   -2.427861    1.571442 
     H       -3.080296   -0.663620    2.600093 
     H       -1.952649   -1.761329    1.705684 
     H       -1.699447    0.856701    1.605182 
     H       -3.499012    1.945970    0.682099 
     H        1.294287    1.083511   -0.967335 
     H        1.130347   -0.631492   -1.553526 
     H        0.371275   -0.998228    0.874979 
     H       -6.672680   -1.990468    0.739689 
     H       -6.017190   -1.836580   -0.941022 
     H       -7.028701   -0.508038   -0.239915 
     H        4.120353    0.368825    1.418483 
     H        2.439380    0.053524    2.020948 
     H        2.165181    3.432857    2.106782 
     H       -1.031703   -1.384873   -1.743526 
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